DK3538134T3 - Trunkeret von willebrand-faktor polypeptider til ekstravaskulær administration til behandling eller profylakse af en blodkoagulationsforstyrrelse - Google Patents
Trunkeret von willebrand-faktor polypeptider til ekstravaskulær administration til behandling eller profylakse af en blodkoagulationsforstyrrelse Download PDFInfo
- Publication number
- DK3538134T3 DK3538134T3 DK17801644.0T DK17801644T DK3538134T3 DK 3538134 T3 DK3538134 T3 DK 3538134T3 DK 17801644 T DK17801644 T DK 17801644T DK 3538134 T3 DK3538134 T3 DK 3538134T3
- Authority
- DK
- Denmark
- Prior art keywords
- prophylaxation
- trunked
- treatment
- blood coagulation
- von willebrand
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16198497 | 2016-11-11 | ||
| PCT/EP2017/078840 WO2018087271A1 (en) | 2016-11-11 | 2017-11-10 | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3538134T3 true DK3538134T3 (da) | 2022-02-07 |
Family
ID=57389201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17801644.0T DK3538134T3 (da) | 2016-11-11 | 2017-11-10 | Trunkeret von willebrand-faktor polypeptider til ekstravaskulær administration til behandling eller profylakse af en blodkoagulationsforstyrrelse |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11890327B2 (da) |
| EP (1) | EP3538134B1 (da) |
| JP (1) | JP2020504082A (da) |
| KR (1) | KR20190073576A (da) |
| CN (1) | CN110381986B (da) |
| AU (1) | AU2017358865A1 (da) |
| CA (1) | CA3043397A1 (da) |
| DK (1) | DK3538134T3 (da) |
| ES (1) | ES2908008T3 (da) |
| SG (2) | SG10201912768YA (da) |
| TW (1) | TW201828974A (da) |
| WO (1) | WO2018087271A1 (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ769677A (en) | 2018-05-18 | 2024-07-05 | Bioverativ Therapeutics Inc | Methods of treating hemophilia a |
| AU2020300820A1 (en) * | 2019-07-04 | 2022-03-03 | CSL Behring Lengnau AG | A truncated von willebrand factor (vWF) for increasing the in vitro stability of coagulation factor VIII |
| WO2021094344A1 (en) | 2019-11-11 | 2021-05-20 | CSL Behring Lengnau AG | Polypeptides for inducing tolerance to factor viii |
| KR102647642B1 (ko) * | 2021-05-04 | 2024-03-15 | (주)케어젠 | 혈액 응고 활성을 갖는 펩타이드와 이의 용도 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
| AU6029594A (en) | 1993-01-15 | 1994-08-15 | Enzon, Inc. | Factor viii - polymeric conjugates |
| SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| IL113010A (en) | 1994-03-31 | 1999-10-28 | Pharmacia & Upjohn Ab | Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
| DE69534265T2 (de) | 1994-12-12 | 2006-05-04 | Beth Israel Deaconess Medical Center, Inc., Boston | Chimäre zytokine und ihre verwendung |
| WO1997003193A1 (en) | 1995-07-11 | 1997-01-30 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered metal-binding properties |
| SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| AT403764B (de) * | 1996-03-15 | 1998-05-25 | Immuno Ag | Stabiler faktor viii/vwf-komplex |
| DE69735421T2 (de) | 1996-04-24 | 2006-10-19 | The Regents Of The University Of Michigan, Ann Arbor | Gegen inaktivierung resistenter faktor viii |
| US20040092442A1 (en) | 1996-04-24 | 2004-05-13 | University Of Michigan | Inactivation resistant factor VIII |
| PT1079805E (pt) | 1998-04-27 | 2005-03-31 | Opperbas Holding Bv | Composicao farmaceutica compreendendo factor viii e lipossomas neutros |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| US7615622B2 (en) | 2001-01-12 | 2009-11-10 | University Of Maryland, Baltimore | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII |
| AU2002310438B2 (en) | 2001-06-14 | 2008-05-01 | The Scripps Research Institute | Stabilized proteins with engineered disulfide bonds |
| AU2003210806A1 (en) | 2002-03-05 | 2003-09-22 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| DE60332011D1 (de) | 2002-04-29 | 2010-05-20 | Sanquin Bloedvoorziening | Antagonisten der interaktion zwischen faktor viii und lrp ("low-density lipoprotein receptor related protein") |
| US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| BRPI0407882B1 (pt) | 2003-02-26 | 2021-07-27 | Nektar Therapeutics | Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| ES2558102T3 (es) | 2003-05-06 | 2016-02-02 | Biogen Hemophilia Inc. | Proteínas quiméricas del factor de coagulación para el tratamiento de un trastorno hemostático |
| EP2368909A1 (en) | 2003-06-12 | 2011-09-28 | Eli Lilly and Company | GLP-1 analog fusion proteins |
| CN1902222A (zh) | 2003-12-31 | 2007-01-24 | 默克专利有限公司 | 具有改善药物代谢动力学的Fc－促红细胞生成素融合蛋白质 |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| HUE033776T2 (en) | 2004-11-12 | 2018-01-29 | Bayer Healthcare Llc | FVIII site-specific modification |
| BRPI0519562A2 (pt) | 2004-12-27 | 2009-01-27 | Baxter Int | construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁcea |
| KR20080007226A (ko) | 2005-04-14 | 2008-01-17 | 체에스엘 베링 게엠베하 | 증가된 안정성을 가진 변형된 응고 인자 ⅷ 및 이의 유도체 |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| CA2647314A1 (en) | 2006-03-31 | 2007-11-08 | Baxter International Inc. | Pegylated factor viii |
| ES2889920T3 (es) | 2006-06-14 | 2022-01-14 | Csl Behring Gmbh | Proteínas de fusión escindibles proteolíticamente con alta actividad específica molar |
| EP3231440A1 (en) | 2006-12-22 | 2017-10-18 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
| EP2486936A1 (en) | 2007-06-13 | 2012-08-15 | CSL Behring GmbH | A composition comprising VWF and FVIII preparations for use in treating of bleeding disorders |
| EP2291523B1 (en) | 2008-06-24 | 2014-12-17 | CSL Behring GmbH | Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life |
| CN102648212B (zh) | 2009-11-13 | 2014-12-03 | 基立福疗法公司 | 包含冯维勒布兰德因子(vWF)的制剂及其相关制备方法、试剂盒和用途 |
| AU2012340501A1 (en) | 2011-12-19 | 2013-07-11 | Grifols, S.A. | Compositions, methods, and kits for preparing sialylated recombinant proteins |
| BR112014017165B1 (pt) | 2012-01-12 | 2023-05-02 | Bioverativ Therapeutics Inc | Proteína quimérica compreendendo uma proteína de fator viii, composição farmacêutica, e seus usos |
| EP2814502B1 (en) | 2012-02-15 | 2017-09-13 | CSL Behring GmbH | Von willebrand factor variants having improved factor viii binding affinity |
| EP2841451A1 (en) | 2012-04-24 | 2015-03-04 | Novo Nordisk A/S | Compounds suitable for treatment of haemophilia |
| US20150045303A1 (en) * | 2012-04-24 | 2015-02-12 | Novo Nordisk A/S | Pharmaceutical Composition Suitable for Treatment of Haemophilia |
| CN104661674A (zh) | 2012-07-11 | 2015-05-27 | 阿穆尼克斯运营公司 | 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途 |
| DK2796145T3 (da) * | 2013-04-22 | 2018-01-29 | Csl Ltd | Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro |
| JP2016522219A (ja) | 2013-06-12 | 2016-07-28 | ノヴォ ノルディスク アー／エス | 血友病の治療に適する化合物 |
| KR20170010895A (ko) | 2014-06-06 | 2017-02-01 | 옥타파마 아게 | 인자 ⅷ 및 폰 빌레브란트 인자 펩티드를 포함하는 조제 |
| DK3164150T3 (da) | 2014-07-02 | 2021-02-08 | CSL Behring Lengnau AG | Modificeret von willebrand-faktor |
| DK3298036T3 (da) | 2015-05-22 | 2022-06-07 | CSL Behring Lengnau AG | Fremgangsmåder til forberedelse af modificeret von Willebrand faktor |
-
2017
- 2017-11-10 CA CA3043397A patent/CA3043397A1/en not_active Abandoned
- 2017-11-10 US US16/349,002 patent/US11890327B2/en active Active
- 2017-11-10 DK DK17801644.0T patent/DK3538134T3/da active
- 2017-11-10 CN CN201780069945.0A patent/CN110381986B/zh active Active
- 2017-11-10 SG SG10201912768YA patent/SG10201912768YA/en unknown
- 2017-11-10 JP JP2019524345A patent/JP2020504082A/ja active Pending
- 2017-11-10 KR KR1020197016644A patent/KR20190073576A/ko not_active Application Discontinuation
- 2017-11-10 TW TW106139051A patent/TW201828974A/zh unknown
- 2017-11-10 EP EP17801644.0A patent/EP3538134B1/en active Active
- 2017-11-10 ES ES17801644T patent/ES2908008T3/es active Active
- 2017-11-10 WO PCT/EP2017/078840 patent/WO2018087271A1/en unknown
- 2017-11-10 SG SG11201903954WA patent/SG11201903954WA/en unknown
- 2017-11-10 AU AU2017358865A patent/AU2017358865A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN110381986A (zh) | 2019-10-25 |
| SG11201903954WA (en) | 2019-05-30 |
| KR20190073576A (ko) | 2019-06-26 |
| SG10201912768YA (en) | 2020-02-27 |
| EP3538134A1 (en) | 2019-09-18 |
| TW201828974A (zh) | 2018-08-16 |
| JP2020504082A (ja) | 2020-02-06 |
| CA3043397A1 (en) | 2018-05-17 |
| ES2908008T3 (es) | 2022-04-27 |
| US11890327B2 (en) | 2024-02-06 |
| EP3538134B1 (en) | 2021-12-29 |
| WO2018087271A1 (en) | 2018-05-17 |
| US20210268071A1 (en) | 2021-09-02 |
| AU2017358865A1 (en) | 2019-05-09 |
| CN110381986B (zh) | 2023-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3668562T3 (da) | Blodpumpe | |
| DK3912673T3 (da) | Blodpumpe | |
| DK3413948T3 (da) | Blodpumpesystem | |
| DK3468568T3 (da) | Ekstracellulære vesikler der er afledt af humantrombo-cytlysat, til anvendelse i medicin | |
| DK3349758T3 (da) | Fremgangsmåder til behandling af arenaviridae-virusinfektioner | |
| DK3521282T3 (da) | Quinazolinderivater anvendt til behandling af hiv | |
| DK3341041T3 (da) | Blodstrømspumpe til ventrikulær assistance | |
| DK3538134T3 (da) | Trunkeret von willebrand-faktor polypeptider til ekstravaskulær administration til behandling eller profylakse af en blodkoagulationsforstyrrelse | |
| DK3290066T3 (da) | Blodpumpe med flowkanyle | |
| DK3302502T3 (da) | Intrapulmonal administration af polynukleotid-agonister af toll-lignende receptor-9 til behandling af lungecancer | |
| MA46284A (fr) | Canule cardiaque | |
| DK3244948T3 (da) | Bestemmelse af medikamentdosis | |
| DK3411393T3 (da) | Administration af manipulerede t-celler til behandling af cancere i centralnervesystemet | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DE112017001906A5 (de) | Kanülenanordnung und Blutpumpenanordnung sowie deren Verwendung | |
| DK3294283T3 (da) | Sacubitril-valsartan-doseringsregime til behandling af hjerteinsufficiens | |
| DK3237045T3 (da) | Indretning til indgivelse af lægemidler | |
| DK3391875T3 (da) | Fremgangsmåde til fremstilling af polymer micelle, der indeholder et anionisk lægemiddel | |
| DK3258919T4 (da) | Næsepulverformulering til behandling af hypoglykæmi | |
| DK3297656T3 (da) | Trunkeret von Willebrand Faktor polypeptider til behandling af hæmofili | |
| DK3468604T3 (da) | Farmaceutiske kombinationer til behandling af cancer | |
| DE112017004905A5 (de) | Blutpumpe | |
| DK3618845T3 (da) | Peptider til behandling af diabetes | |
| DK3585808T3 (da) | Modificerede serpiner til behandlingen af bradykinin formidlet sygdom | |
| DK3538133T3 (da) | Trunkeret von willebrand faktor polypeptider til behandling af hæmofili |